Health Trials

About this trial

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Eligibility criteria

Qualifiers

Must be ≥18 years of age

Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

First-line PDAC participants will have received no previous systemic anti-cancer therapy

Disqualifiers

Inability to swallow oral medications

Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma

Participants with only locally advanced disease

Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Trial design

Treatments tested in this trial

  • Atebimetinib
  • GnP
  • mGnP

Treatment groups

510 Participants
are divided into 2 treatment groups

Locations

19
Australia
Calvary Mater Newcastle2298, WaratahNew South Wales, Australia
Icon Cancer Centre - Chermside4032, ChermsideQueensland, Australia
United States
Arizona
City of Hope85338, Phoenix United States
California
City of Hope91010, Duarte United States

Sponsors and collaborators

Immuneering Corporation

Lead sponsor

Source ClinicalTrials.gov